ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company has responded to the warning letter and carried out the committed corrections.
Subscribe To Our Newsletter & Stay Updated
